Biotech News
Related news
OCSOculis2026-04-20 08:00 EST
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
OCSOculis2026-05-29 19:06 EST
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
OCGNOcugen2026-07-31 11:02 EST
Ocugen to Participate in Upcoming August Investor Conferences
OCGNOcugen2026-06-02 11:03 EST
Ocugen to Participate in Upcoming June Investor and Industry Conferences
TARSTarsus Pharmaceuticals2026-05-28 20:30 EST
Tarsus to Participate in Upcoming Investor Conferences
LENZLenz Therapeutics Inc2026-05-26 12:00 EST
LENZ Therapeutics to Participate in Upcoming Investor Conferences
BLTEBelite Bio2026-04-23 12:00 EST
Belite Bio to Participate in Four Upcoming Investor Conferences
OCULOcular Therapeutix2026-07-01 11:00 EST
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
OKYOOKYO Pharma2026-04-29 11:00 EST
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
OCULOcular Therapeutix2026-04-27 11:00 EST
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-08-06 20:05 EST
Oculis Reports Q2 2026 Financial Results and Provides Company Update
OCSOculis2026-08-03 08:00 EST
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
OCSOculis2026-07-08 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
OCSOculis2026-07-02 08:00 EST
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Stock data
- Close
- 12.38 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States